{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:43:25Z","timestamp":1787906605787,"version":"build-2784847793"},"reference-count":186,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ontario Ministry of Health"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ctrv.2020.102032","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T12:28:45Z","timestamp":1590582525000},"page":"102032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review"],"prefix":"10.1016","volume":"87","author":[{"given":"Tara D.","family":"Baetz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0676-7416","authenticated-orcid":false,"given":"Glenn G.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"McWhirter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Rajagopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinni","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa M.","family":"Petrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2020.102032_b0005","first-page":"e23","article-title":"Mucosal melanoma: New insights and therapeutic options for a unique and aggressive disease","volume":"31","author":"Lerner","year":"2017","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ctrv.2020.102032_b0010","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/cncr.20866","article-title":"Incidence of noncutaneous melanomas in the U.S","volume":"103","author":"McLaughlin","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0015","first-page":"472","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2020.102032_b0020","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clon.2011.12.002","article-title":"Adjuvant interferon therapy for patients at high risk for recurrent melanoma: An updated systematic review and practice guideline","volume":"24","author":"Petrella","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0025","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cncr.21760","article-title":"Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma","volume":"106","author":"Verma","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0030","unstructured":"Petrella TM, Baetz TD, Fletcher GG, Knight G, McWhirter E, Rajagopal S, et al. Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma [Internet]. Toronto (ON): Cancer Care Ontario; 2019 Aug. Program in Evidence-Based Care Evidence-Based Series No.: 8-1 version 5; 2019. Available from: https:\/\/www.cancercareontario.ca\/en\/guidelines-advice\/types-of-cancer\/1161."},{"key":"10.1016\/j.ctrv.2020.102032_b0035","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.3747\/co.27.5933","article-title":"Systemic adjuvant therapy for adult patients at high risk for recurrent cutaneous or mucosal melanoma: An Ontario Health (Cancer Care Ontario) clinical practice guideline","volume":"27","author":"Petrella","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0040","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2020.102032_b0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2017.06.006","article-title":"Adjuvant interferon-alpha for the treatment of high-risk melanoma: An individual patient data meta-analysis","volume":"82","author":"Ives","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0050","article-title":"Interferon alpha for the adjuvant treatment of cutaneous melanoma","volume":"6","author":"Mocellin","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2020.102032_b0055","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(14)70110-X","article-title":"Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): Preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study","volume":"15","author":"Corrie","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0060","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1093\/annonc\/mdy229","article-title":"Adjuvant bevacizumab for melanoma patients at high risk of recurrence: Survival analysis of the AVAST-M trial","volume":"29","author":"Corrie","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0065","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/annonc\/mdx717","article-title":"Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma","volume":"29","author":"Lee","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0070","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102032_b0075","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2020.102032_b0080","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.ijrobp.2017.06.193","article-title":"Regional Lymph Node Basin (RLNB) Relapse after Adjuvant Ipilimumab (Ipi) Anti-CTLA4 Immunotherapy in Stage III Melanoma: A Subgroup Analysis of a Randomized Placebo-Controlled Trial","volume":"99","author":"Barker","year":"2017","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2020.102032_b0085","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(17)30015-3","article-title":"Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): Secondary outcomes of a multinational, randomised, double-blind, phase 3 trial","volume":"18","author":"Coens","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0090","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.2512","article-title":"Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial","volume":"37","author":"Eggermont","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0095","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9500","article-title":"A phase III randomized study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms","volume":"35","author":"Tarhini","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9504","article-title":"United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon-\u03b12b for resected high-risk melanoma","volume":"37","author":"Tarhini","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0105","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102032_b0110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9502","article-title":"Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III\/IV melanoma: Updated results from a phase III trial (CheckMate 238)","volume":"36","author":"Weber","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0115","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9584","article-title":"An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238)","volume":"37","author":"Mandal\u00e0","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9593","article-title":"Indirect treatment comparison of nivolumab versus placebo as an adjuvant therapy for resected melanoma","volume":"36","author":"Shoushtari","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0125","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9594","article-title":"Assessing the value of nivolumab (NIVO) versus placebo (PBO) and ipilimumab (IPI) as adjuvant therapy for resected melanoma","volume":"36","author":"Freeman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0130","first-page":"93","article-title":"Quality of life indirect treatment comparisons of nivolumab versus placebo as adjuvant treatment for melanoma","volume":"32","author":"Hemstock","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102032_b0135","first-page":"94","article-title":"Evaluating the relative efficacy of nivolumab versus placebo as adjuvant treatment for melanoma using multiple methods of indirect treatment comparison","volume":"32","author":"Hemstock","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102032_b0140","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102032_b0145","unstructured":"Coens C, Bottomley A, Blank CU, Mandala M, Long GV, Atkinson V, et al. Health-related quality-of-life for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Results from the EORTC 1325-MG\/Keynote 054 trial - an international randomized double-blind phase 3 trial [conference poster] [Internet]; 2018 Oct 11 [cited 2018 Oct 23]. ESMO 2018 conference, Munich Germany, 2018 Oct 19-23, poster 5085 (1278P on poster); 2018. Available from: https:\/\/poster-submission.com\/esmo2018\/visitors\/eposter\/38130."},{"key":"10.1016\/j.ctrv.2020.102032_b0150","doi-asserted-by":"crossref","unstructured":"Coens C, Bottomley A, Blank CU, Mandala M, Long GV, Atkinson VG, et al. Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG\/Keynote 054 trial: An international randomized double-blind phase 3 trial. Ann Oncol. 2018;29:viii456. Abstract 1278P.","DOI":"10.1093\/annonc\/mdy289.034"},{"key":"10.1016\/j.ctrv.2020.102032_b0155","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1470-2045(18)30106-2","article-title":"Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"19","author":"Maio","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0160","first-page":"13","article-title":"Prognostic impact of baseline tumor immune infiltrate on disease-free survival (DFS) in patients with completely resected, BRAFV600 mutation-positive (BRAFV600+) melanoma receiving adjuvant vemurafenib","volume":"16","author":"Schadendorf","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.ctrv.2020.102032_b0165","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.18.01219","article-title":"Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600\u2013mutant stage III melanoma","volume":"36","author":"Hauschild","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0170","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102032_b0175","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1470-2045(18)30940-9","article-title":"Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): A randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Schadendorf","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0180","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9590","article-title":"Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma","volume":"36","author":"Schadendorf","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0185","doi-asserted-by":"crossref","first-page":"viii446","DOI":"10.1093\/annonc\/mdy289.007","article-title":"Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial","volume":"29","author":"Atkinson","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0190","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9582","article-title":"Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO)","volume":"37","author":"Schadendorf","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0195","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1200\/JCO.1995.13.11.2776","article-title":"Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma","volume":"13","author":"Creagan","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0205","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.1996.14.10.2666","article-title":"Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study","volume":"14","author":"Cole","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0210","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-1103-3","article-title":"A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma","volume":"10","author":"Kirkwood","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.ctrv.2020.102032_b0215","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1002\/cncr.32162","article-title":"An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma","volume":"125","author":"Najjar","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0220","first-page":"1311","article-title":"Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2b for high-risk melanoma patients using Intergroup clinical trial data","volume":"20","author":"Kilbridge","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0225","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","article-title":"High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690\/S9111\/C9190","volume":"18","author":"Kirkwood","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0230","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/cncr.10775","article-title":"Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: The E2690 laboratory corollary of intergroup adjuvant trial E1690","volume":"95","author":"Kirkwood","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0235","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.2002.08.024","article-title":"Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: Pathologic corollary of Eastern Cooperative Oncology Group trial E1690","volume":"20","author":"Rao","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0240","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","article-title":"High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH\/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694\/S9512\/C509801","volume":"19","author":"Kirkwood","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0245","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.2015.63.3776","article-title":"Final results of the Sunbelt Melanoma Trial: A multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy","volume":"34","author":"McMasters","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0250","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1245\/s10434-015-5074-2","article-title":"Melanoma patient-reported quality of life outcomes following sentinel lymph node biopsy, completion lymphadenectomy, and adjuvant interferon: Results from the Sunbelt Melanoma Trial","volume":"23","author":"Egger","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0255","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.surg.2015.12.002","article-title":"Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes","volume":"159","author":"Egger","year":"2016","journal-title":"Surgery"},{"key":"10.1016\/j.ctrv.2020.102032_b0260","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1245\/s10434-012-2701-z","article-title":"Diversity of stage III melanoma in the era of sentinel lymph node biopsy","volume":"20","author":"Egger","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0265","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/lary.23793","article-title":"Sentinel lymph node status is the most important prognostic factor in patients with melanoma of the scalp","volume":"123","author":"Cappello","year":"2013","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ctrv.2020.102032_b0270","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/000313481107700219","article-title":"Prognostic significance of tumor infiltrating lymphocytes in melanoma","volume":"77","author":"Burton","year":"2011","journal-title":"Am Surg"},{"key":"10.1016\/j.ctrv.2020.102032_b0275","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1177\/000313481107700819","article-title":"Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma","volume":"77","author":"Burton","year":"2011","journal-title":"Am Surg"},{"key":"10.1016\/j.ctrv.2020.102032_b0280","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/jso.20084","article-title":"Lessons learned from the Sunbelt Melanoma Trial","volume":"86","author":"McMasters","year":"2004","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0285","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1245\/ASO.2004.04.015","article-title":"Correlation between prognostic factors and increasing age in melanoma","volume":"11","author":"Chao","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0290","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1200\/JCO.2008.16.3121","article-title":"Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma","volume":"27","author":"Pectasides","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0295","first-page":"1947","article-title":"Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year - A Hellenic Cooperative Oncology Group study","volume":"24","author":"Gogas","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2020.102032_b0300","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"354","author":"Gogas","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102032_b0305","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1200\/JCO.2016.70.2951","volume":"35","author":"Agarwala","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0310","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1200\/JCO.2013.53.1590","volume":"32","author":"Flaherty","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0315","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.8513","volume":"28","author":"Sosman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0320","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.8517","article-title":"Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from SWOG S0008","volume":"28","author":"Sondak","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0325","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1002\/cam4.1223","article-title":"High frequency of brain metastases after adjuvant therapy for high-risk melanoma","volume":"6","author":"Samlowski","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2020.102032_b0330","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/CMR.0b013e328314b84a","article-title":"A randomized phase III trial of biochemotherapy versus interferon-alpha- 2b for adjuvant therapy in patients at high risk for melanoma recurrence","volume":"19","author":"Kim","year":"2009","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102032_b0335","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9589","article-title":"Phase III randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma","volume":"36","author":"Lian","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0340","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1158\/1078-0432.CCR-13-0739","article-title":"Phase II randomized trial comparing high-dose IFN-alpha2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma","volume":"19","author":"Lian","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102032_b0345","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1200\/JCO.2014.59.6932","article-title":"Intermittent high-dose intravenous interferon alfa-2b for adjuvant treatment of stage III melanoma: Final analysis of a randomized phase III dermatologic cooperative oncology group trial","volume":"33","author":"Mohr","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0350","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8506","article-title":"Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]","volume":"29","author":"Chiarion-Sileni","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0355","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-6-44","article-title":"Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: A randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]","volume":"6","author":"Chiarion-Sileni","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0360","doi-asserted-by":"crossref","first-page":"e20028","DOI":"10.1200\/jco.2013.31.15_suppl.e20028","article-title":"Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis of two randomized phase III trials (NCT00226408 and ISRCTN75125874) with 980 patients","volume":"31","author":"Weichenthal","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0365","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2015.11.014","article-title":"Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity","volume":"55","author":"Eggermont","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0370","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejca.2011.09.028","article-title":"Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991","volume":"48","author":"Eggermont","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0375","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(05)67482-X","article-title":"Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb\/III melanoma (EORTC 18952): Randomised controlled trial","volume":"366","author":"Eggermont","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2020.102032_b0380","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ejca.2010.10.005","article-title":"Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: A corollary study to EORTC trial 18952","volume":"47","author":"Bouwhuis","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0385","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/CMR.0b013e328346c17f","article-title":"Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-alpha (EORTC 18952) and prognostic value on treatment outcome","volume":"21","author":"Bouwhuis","year":"2011","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102032_b0390","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jnci\/djp132","article-title":"Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon","volume":"101","author":"Bouwhuis","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2020.102032_b0395","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1470-2045(10)70288-6","article-title":"Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): A randomised phase 3 trial","volume":"12","author":"Hansson","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0400","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.ejca.2011.11.019","article-title":"Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b","volume":"48","author":"Brandberg","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0405","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3109\/0284186X.2013.789140","article-title":"Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma","volume":"52","author":"Brandberg","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0410","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00262-014-1620-1","article-title":"Benefit of adjuvant interferon alfa-2b (IFN-alpha) therapy in melanoma patients with high serum MMP-8 levels","volume":"64","author":"Vihinen","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2020.102032_b0415","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00262-015-1686-4","article-title":"Evaluation of serum osteopontin level and gene polymorphism as biomarkers: Analyses from the Nordic Adjuvant Interferon Alpha melanoma trial","volume":"64","author":"Prasmickaite","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2020.102032_b0420","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/CMR.0000000000000237","article-title":"Prognostic and predictive value of YKL-40 in stage IIB-III melanoma","volume":"26","author":"Krogh","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102032_b0425","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1200\/JCO.2006.10.1709","article-title":"Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon alfa-2b for resected stage III cutaneous melanoma","volume":"25","author":"Mitchell","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0430","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(97)12445-X","article-title":"Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases","volume":"351","author":"Grob","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2020.102032_b0435","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0959-8049(00)00411-1","article-title":"Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma","volume":"37","author":"Lafuma","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0440","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1200\/JCO.1998.16.4.1425","article-title":"Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma","volume":"16","author":"Pehamberger","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0445","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1054\/bjoc.2000.1623","article-title":"Adjuvant interferon alpha 2b in high risk melanoma - The Scottish Study","volume":"84","author":"Cameron","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0450","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0140-6736(01)06068-8","article-title":"Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial","volume":"358","author":"Cascinelli","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2020.102032_b0455","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1200\/JCO.2004.03.185","article-title":"Adjuvant interferon in high-risk melanoma: The AIM HIGH study - United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma","volume":"22","author":"Hancock","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0460","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.bjc.6602973","article-title":"Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: Results from randomised trial","volume":"94","author":"Dixon","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0465","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/annonc\/mdn001","article-title":"Adjuvant low-dose interferon alpha2a with or without dacarbazine compared with surgery alone: A prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis","volume":"19","author":"Garbe","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0470","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2009.23.1704","article-title":"Efficacy of low-dose interferon alpha2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: Results of a randomized phase III DeCOG trial","volume":"28","author":"Hauschild","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0475","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/CJI.0b013e3181b8bdb9","article-title":"Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: Results from the multicenter DeCOG trial","volume":"33","author":"Heinze","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.ctrv.2020.102032_b0480","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ejca.2003.07.004","article-title":"Final results of the EORTC 18871\/DKG 80\u20131 randomised phase III trial: rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis","volume":"40","author":"Kleeberg","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0485","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/02841860600630954","article-title":"Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial","volume":"45","author":"Stadler","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0490","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.2011.41.3799","article-title":"Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma","volume":"30","author":"Eggermont","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0495","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.2008.20.2069","volume":"27","author":"Bottomley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0500","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1016\/j.ejca.2009.09.004","article-title":"Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)","volume":"45","author":"Fusi","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0505","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2009.24.6264","article-title":"Phase III trial comparing adjuvant treatment with pegylated interferon alfa-2b versus observation: Prognostic significance of autoantibodies - EORTC 18991","volume":"28","author":"Bouwhuis","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0510","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00280-009-1072-z","article-title":"Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991)","volume":"65","author":"Eggermont","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2020.102032_b0515","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00262-013-1428-4","article-title":"Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)","volume":"62","author":"Busse","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2020.102032_b0520","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/annonc\/mdw225","article-title":"Adjuvant treatment with pegylated interferon alpha-2a versus low-dose interferon alpha-2a in patients with high-risk melanoma: A randomized phase III DeCOG trial","volume":"27","author":"Eigentler","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0525","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/jnci\/87.22.1710","article-title":"Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: A Southwest Oncology Group study","volume":"87","author":"Meyskens","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2020.102032_b0530","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/cncr.20166","volume":"100","author":"Agarwala","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0535","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1002\/1097-0142(19810601)47:11<2556::AID-CNCR2820471107>3.0.CO;2-J","article-title":"DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) surgical adjuvant study COG PROTOCOL 7040","volume":"47","author":"Hill","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0540","first-page":"S81","article-title":"An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin. A phase III adjuvant study. EORTC protocol 18761","volume":"24","author":"Lejeune","year":"1988","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0545","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM198210073071503","article-title":"A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma","volume":"307","author":"Veronesi","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102032_b0550","first-page":"929","article-title":"Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases","volume":"128","author":"Quirt","year":"1983","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.ctrv.2020.102032_b0555","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/0959-8049(93)90531-J","article-title":"Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma","volume":"29","author":"Karakousis","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0560","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0039-6109(16)42582-X","article-title":"Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial","volume":"61","author":"Fisher","year":"1981","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.ctrv.2020.102032_b0565","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/00000421-200212000-00003","article-title":"Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (megace) in selected patients with malignant melanoma","volume":"25","author":"Markovic","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0570","doi-asserted-by":"crossref","first-page":"8655","DOI":"10.1200\/JCO.2004.00.8128","article-title":"Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group","volume":"23","author":"Richtig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0575","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/CMR.0b013e32830e3936","article-title":"Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: A randomized multicenter trial of the German Dermatologic Cooperative Oncology Group","volume":"18","author":"Eigentler","year":"2008","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102032_b0580","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/02656736.2014.931601","article-title":"Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities - Long-term follow-up of a randomised trial","volume":"30","author":"Olofsson Bagge","year":"2014","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.ctrv.2020.102032_b0585","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1200\/JCO.1991.9.12.2091","article-title":"Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group","volume":"9","author":"Hafstrom","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0590","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1200\/JCO.1998.16.9.2906","volume":"16","author":"Schraffordt Koops","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0595","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1053\/ejso.1999.0686","article-title":"Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan","volume":"25","author":"Vrouenraets","year":"1999","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0600","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0748-7983(97)80134-5","article-title":"A randomized controlled trial of prophylactic isolated cytotoxic perfusion for poor-prognosis primary melanoma of the lower limb","volume":"23","author":"Fenn","year":"1997","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0605","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/BF01658878","article-title":"Hyperthermic perfusion with chemotherapy for melanoma of the extremities","volume":"13","author":"Ghussen","year":"1989","journal-title":"World J Surg"},{"key":"10.1016\/j.ctrv.2020.102032_b0610","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/1097-0142(19880215)61:4<654::AID-CNCR2820610406>3.0.CO;2-V","article-title":"The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma","volume":"61","author":"Ghussen","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0615","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1445-2197.1978.tb05804.x","article-title":"Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases","volume":"48","author":"Morton","year":"1978","journal-title":"Aust N Z J Surg"},{"key":"10.1016\/j.ctrv.2020.102032_b0620","series-title":"Immunotherapy of Human Cancer","first-page":"245","article-title":"Adjuvant immunotherapy: Results of a randomized trial in patients with lymph node metastases","author":"Morton","year":"1982"},{"key":"10.1016\/j.ctrv.2020.102032_b0625","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1200\/JCO.2002.12.094","article-title":"Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: Results of a randomized trial","volume":"20","author":"Hersey","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0630","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3892\/mco.2013.97","article-title":"Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma","volume":"1","author":"Suriano","year":"2013","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0635","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1072-7515(98)00097-0","article-title":"Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial","volume":"187","author":"Wallack","year":"1998","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ctrv.2020.102032_b0640","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/BF02305788","article-title":"Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial","volume":"3","author":"Wallack","year":"1996","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0645","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00000658-199708000-00012","article-title":"Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: Second interim analysis of data from a phase III, multi- institutional trial","volume":"226","author":"Wallack","year":"1997","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2020.102032_b0650","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1200\/JCO.1994.12.5.1036","article-title":"Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside","volume":"12","author":"Livingston","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0655","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2012.47.9303","article-title":"Adjuvant ganglioside GM2-KLH\/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: Results of the EORTC 18961 randomized phase III trial","volume":"31","author":"Eggermont","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0660","doi-asserted-by":"crossref","first-page":"e1428157","DOI":"10.1080\/2162402X.2018.1428157","article-title":"Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial","volume":"7","author":"Michels","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ctrv.2020.102032_b0665","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.8508","article-title":"An international, randomized, phase III trial of Bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites","volume":"25","author":"Morton","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0670","unstructured":"CancerVax. CancerVax announces results of phase 3 clinical trials of Canvaxin\u2122 in patients with stage III and stage IV melanoma [news release]. March 24, 2006 [cited 2018 Sep 12]; 2006. Available from: http:\/\/www.marketwired.com\/press-release\/cancervax-announces-results-phase-3-clinical-trials-canvaxin-patients-with-stage-iii-nasdaq-cnvx-675445.htm or https:\/\/www.sec.gov\/Archives\/edgar\/containers\/fix060\/1131907\/000093639206000264\/a18983e425.htm."},{"key":"10.1016\/j.ctrv.2020.102032_b0675","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2011.40.0887","article-title":"Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial","volume":"30","author":"Hoshimoto","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0680","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1245\/s10434-017-6072-3","article-title":"Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases","volume":"24","author":"Faries","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0685","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/SLA.0b013e3182380f56","article-title":"Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma","volume":"255","author":"Hoshimoto","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2020.102032_b0690","first-page":"1882","article-title":"Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine","volume":"7","author":"Bystryn","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102032_b0695","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2015.62.0500","volume":"33","author":"Lawson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0700","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/1078-0432.CCR-16-3016","article-title":"Immune correlates of GM-CSF and melanoma peptide vaccination in a randomized trial for the adjuvant therapy of resected high-risk melanoma (E4697)","volume":"23","author":"Butterfield","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102032_b0705","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0710","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJM198011133032003","article-title":"A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma","volume":"303","author":"Spitler","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102032_b0715","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1200\/JCO.1991.9.5.736","article-title":"A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma","volume":"9","author":"Spitler","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0720","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.1991.9.5.729","article-title":"Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: A phase III study by the National Cancer Institute of Canada Clinical Trials Group","volume":"9","author":"Quirt","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0725","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8533","article-title":"Phase II study of recombinant adeno-viral human p53 (rAd-p53) gene therapy combined with surgery in treatment of melanomas of oral mucosa","volume":"29","author":"Li","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0730","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.2008.21.3892","article-title":"Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node - negative melanoma","volume":"27","author":"Hauschild","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0735","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1200\/JCO.2003.07.116","article-title":"Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis","volume":"21","author":"Hauschild","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0740","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2354::AID-CNCR9>3.0.CO;2-L","article-title":"Postsurgical adjuvant therapy for melanoma: Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up","volume":"79","author":"Rusciani","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0745","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejca.2012.07.018","article-title":"Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study","volume":"49","author":"Grob","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0750","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/bmj.1.6060.540","article-title":"Controlled trial of active immunotherapy in management of stage IIB malignant melanoma","volume":"1","author":"McIllmurray","year":"1977","journal-title":"Br Med J"},{"key":"10.1016\/j.ctrv.2020.102032_b0755","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/1097-0142(197904)43:4<1297::AID-CNCR2820430417>3.0.CO;2-9","article-title":"Adjuvant immunotherapy of malignant melanoma","volume":"43","author":"Aranha","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0760","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1158\/2326-6066.CIR-14-0052","article-title":"Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: Long-term outcome and impact of HLA class I antigen expression on overall survival","volume":"2","author":"Carson","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2020.102032_b0765","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1200\/JCO.2002.08.071","article-title":"Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group","volume":"20","author":"Sondak","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0770","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1200\/JCO.2002.08.072","article-title":"Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome","volume":"20","author":"Sosman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0775","first-page":"325","article-title":"Double blind randomized prospective trial of levamisole\/placebo in stage I cutaneous malignant melanoma","volume":"10","author":"Loutfi","year":"1987","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.ctrv.2020.102032_b0780","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0959-8049(93)90064-M","article-title":"Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781)","volume":"29A","author":"Czarnetzki","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0785","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000246222","article-title":"Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781)","volume":"193","author":"Henz","year":"1996","journal-title":"Dermatology"},{"key":"10.1016\/j.ctrv.2020.102032_b0790","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/978-3-642-81685-7_40","article-title":"Clinical trials of chemotherapy and chemoimmunotherapy in primary malignant melanoma","volume":"80","author":"Jacquillat","year":"1982","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102032_b0795","unstructured":"Tranum B, Frank J, Quagliana J, Costanzi J. Adjuvant chemotherapy for stage I melanoma: A SWOG study. Proceedings of ASCO ASCO Abstracts, 1982. 1982:182. Abstract C-710."},{"key":"10.1016\/j.ctrv.2020.102032_b0800","first-page":"643","article-title":"Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: A Southwest Oncology Group study","volume":"71","author":"Tranum","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.ctrv.2020.102032_b0805","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00000421-198502000-00045","article-title":"Adjuvant chemotherapy of malignant melanoma. A pilot study","volume":"8","author":"Hansson","year":"1985","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0810","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/jso.2930360404","article-title":"Adjuvant treatment of malignant melanoma with DTIC + Estracyt or BCG","volume":"36","author":"Karakousis","year":"1987","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0815","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0748-7983(95)97305-2","article-title":"Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma","volume":"21","author":"Kerin","year":"1995","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0820","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/jjco\/hyx063","article-title":"Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II\/III cutaneous melanoma: Japan Clinical Oncology Group study (JCOG1309, J-FERON)","volume":"47","author":"Namikawa","year":"2017","journal-title":"Jpn J Clin Oncol"},{"issue":"May","key":"10.1016\/j.ctrv.2020.102032_b0825","volume":"8","author":"Mordoh","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2020.102032_b0830","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3389\/fimmu.2018.02531","article-title":"Dissecting the immune stimulation promoted by CSF-470 vaccine plus adjuvants in cutaneous melanoma patients: Long term antitumor immunity and short term release of acute inflammatory reactants","volume":"9","author":"Pampena","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102032_b0835","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3538-4","article-title":"Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): A randomized controlled trial","volume":"17","author":"De Smedt","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0840","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e21032","article-title":"SWOG S1404: A phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanoma","volume":"34","author":"Grossmann","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0845","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2016-CT125","article-title":"A phase III randomized trial comparing FDA approved standard of care adjuvant therapy to one year of pembrolizumab in patients with high risk resected melanoma. SWOG 1404","volume":"76","author":"Grossmann","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102032_b0850","first-page":"167","article-title":"Phase 3 KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma","volume":"6","author":"Luke","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0855","first-page":"134","article-title":"Adjuvant therapy with pembrolizumab (Pembro) vs. placebo in resected high-risk stage II melanoma: The phase 3 KEYNOTE-716 study","volume":"32","author":"Luke","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102032_b0860","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS9596","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study","volume":"37","author":"Carlino","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0865","unstructured":"Higgins JPT, Sovovic J, Page MJ, Sterne JAC, on behalf of the ROB2 Development Group. Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) [Internet]. Risk of Bias Info; 2019 Mar 15 (cited 2019 Apr 5); 2019. Available from: https:\/\/www.riskofbias.info\/welcome\/rob-2-0-tool\/current-version-of-rob-2."},{"key":"10.1016\/j.ctrv.2020.102032_b0870","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for a systematic review and meta-analysis of individual participant data: The PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2020.102032_b0875","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jmoldx.2013.07.003","article-title":"Detection of BRAF V600 mutations in metastatic melanoma: Comparison of the Cobas 4800 and Sanger sequencing assays","volume":"15","author":"Qu","year":"2013","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ctrv.2020.102032_b0880","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: A move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2020.102032_b0885","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/cncr.23251","article-title":"Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: Expert opinion","volume":"112","author":"Hauschild","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102032_b0890","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/14740338.2017.1343301","article-title":"The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma","volume":"16","author":"Trinh","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ctrv.2020.102032_b0895","first-page":"633","article-title":"Adjuvant treatment for patients with surgically resected advanced-stage melanoma","volume":"13","author":"Grossmann","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0900","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1470-2045(03)01117-3","article-title":"Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: A systematic review of randomised controlled trials","volume":"4","author":"Lens","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0905","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1245\/ASO.2004.12.042","article-title":"Isolated limb perfusion: What is the evidence for its use?","volume":"11","author":"Noorda","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0910","unstructured":"Wright FC, Kellett S, Sun A, Hanna T, Nessim C, Look Hong NJ, et al. Locoregional management of satellite and in-transit metastasis in melanoma. Program in Evidence-Based Care guideline no.: 8-10 [Internet]. Toronto: Cancer Care Ontario; 2020. Available from: https:\/\/www.cancercareontario.ca\/en\/guidelines-advice\/types-of-cancer\/skin."},{"key":"10.1016\/j.ctrv.2020.102032_b0915","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","article-title":"Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium","volume":"20","author":"Amaria","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0920","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102032_b0925","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): A multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102032_b0930","doi-asserted-by":"crossref","first-page":"MMT11","DOI":"10.2217\/mmt-2018-0003","article-title":"Combatting mucosal melanoma: Recent advances and future perspectives","volume":"5","author":"Tyrrell","year":"2018","journal-title":"Melanoma Manag"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:22:39Z","timestamp":1759656159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220300700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":186,"alternative-id":["S0305737220300700"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102032","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102032"}}